Graft engineering procedures for hematopoietic SCT (HSCT) may improve the chance of success in matched unrelated donor (MUD) and haploidentical donor transplantations. Successful donor immune reconstitution is important to mediate GVL effects in reduced-intensity conditioning (RIC) HSCT. We prospectively investigated early immune reconstitution and clinical outcome in 30 CD3/CD19-depleted MUD (n ¼ 15) or HP (n ¼ 15) HSCTs for high-risk childhood leukemia using a fludarabine-based RIC without serotherapy. The graft consisted of a mean of 10.5 Â 10 6 /kg CD34 þ , 77 Â 10 3 /kg CD3 þ and 39 Â 10 6 /kg CD56 þ cells. After transplantation, 86% of the patients engrafted. In all, 13% of patients had 4grade 3 acute GVHD. Natural killer (NK) cell, DC and T-cell recovery achieved normal values within the first 60 days after transplantation. DC recovery was dominated by the DC2 À subset. NK-cell phenotype was altered and cytotoxicity was lower compared with their donors. EFS was 50 ± 9% (73 ± 11% for those in CR1 and 26 ± 11% for those with advanced disease). Faster DC2
INTRODUCTION
Alternative donors, including match unrelated donors (MUD) and haploidentical (HP) related donors, are increasingly used in hematopoietic SCT (HSCT) for high-risk childhood leukemia. 1, 2 T-cell-depleted grafts have been proposed as a strategy to avoid GVHD. For example, CD34-selected HSCT followed by DLI has been proposed to maximize the effects of GVL with low rates of GVHD in HLA-matched HSCT. 3 However, secondary graft rejection is an important problem, especially in the MUD transplant setting. To facilitate engraftment, CD3/CD19-depleted grafts containing different pools of cells have been proposed to be preferable to T-cell-depleted grafts in MUD and HP HSCT in our unit. 4 In addition to T-cell depletion, B-cell depletion was used to prevent EBV-related lymphoproliferative disease. To reduce toxicity, we developed a reduced intensity conditioning (RIC) with i.v. BU, fludarabine and thiotepa. In addition, a high-dose steroid was used to further suppress recipient T-cell function to prevent graft rejection. We did not use antithymocyte globulin because of its long half-life and its potential to suppress T cells and natural killer (NK) cells, resulting in a high risk of infection and reduced GVL. 5 Clinical GVL effect has been associated with a fast recovery of alloreactive effector cells, such as NK cells in HP settings and T cells in MUD settings. 6, 7 A recent report has described a delay in T-cell reconstitution using CD3/CD19-depleted grafts and RIC in the HP setting. 8 Furthermore, Dulphy et al. 9 have described an immature NK-cell population during the early post-transplant period following unmanipulated HLA-matched HSCTs. Apart from effector cells, the reconstitution of other immune cells such as DCs has not been systematically studied after T-cell-depleted HSCTs.
As DCs are professional APCs, they may have an important role in GVL and infection control. However, studies in children receiving myeloablative conditioning have associated DC recovery with severe acute GVHD. 10, 11 In an adult setting with RIC, low DC recovery has been associated with a higher probability of treatment-related mortality. 12 In this study, we prospectively performed a detailed analysis of immune reconstitution in MUD and HP HSCT with CD3/CD19-depleted grafts in 30 pediatric patients to identify specific cells that may mediate an early GVL effect. Because of the important role of NK cells in an HP setting, 6 we also investigated the expression of inhibitory and activating NK receptors as well as NK-cell cytotoxicity. In contrast to published data from other groups, we found a fast recovery in T, dendritic and NK cells and slow recovery in B lymphocytes and the NKT population. We also observed that delayed lymphoid DC (DC-2) recovery was associated with worse survival. Finally, in an HP setting, we observed an immature NK-cell state that could be improved by a-CpG or IL-15 stimulation. We also observed how NK-cell alloreactivity predicted by ligand--ligand models impacts in relapse events.
MATERIALS AND METHODS
Our local ethics committee approved this study protocol and all patients' guardians gave their informed consent to this study. (Table 1). Patients received non-myeloablative conditioning with fludarabine (130 mg/m 2 ), i.v. BU (according to body weight 3.2 --4.8 mg/kg/day for 2 days), thiotepa (10 mg/kg) and methylprednisolone (4 mg/kg day for 5 days). All patients received PBSCs. MUDs were mobilized according to local hospital policy. HP donors were mobilized by means of a (nonglycosylated G-CSF; Amgen, Thousand Oaks, CA, USA) as reported previously. 13 Graft manipulation was performed by means of CD3/CD19 depletion (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). Patients received CD3/CD19-depleted grafts with a mean CD34 þ stem-cell number of 10.5 Â 10 6 /kg (range: 3.4 --53.5 Â 10 6 /kg), a mean CD3 þ T-cell number of 77 Â 10 3 /kg (range: 3 --460 Â 10 3 /kg) and a mean CD3À/ CD56 þ NK-cell number of 39 Â 10 6 /kg (range: 2.5 --145 Â 10 6 /kg). GVHD prophylaxis consisted of cyclosporine (CYA). Cyclosporine was stopped between days þ60 and þ100.
Engraftment and chimerism
Hematopoietic recovery after transplantation was defined as the first day of achieving an ANC of X0.5 Â 10 9 /L on three consecutive measurements and platelets X20 Â 10 9 /L unsupported for at least 7 days. Hematopoietic donor cell chimerism studies were carried out on genomic DNA obtained from PBMCs by Ficoll density gradient centrifugation taken on days 30, 60 and 90. Samples were amplified by PCR with a panel of six STRs and a variable number of tandem repeat markers. Additional lineage-specific T-cell chimerism was tested in 15 patients by CD3 cell magnetic separation using a CD3 micro bead kit from Miltenyi Biotech. Blood samples were collected from donors and recipients before transplantation, and at 30, 60 and 90 days after HSCT. Immune phenotype and NK cytotoxicity in HP donors were investigated on non-mobilized PBMC cells before mobilization.
Antibodies and flow-cytometry analysis NK-cell, T-cell, B-cell, NKT-cell and DC phenotyping was performed on fresh samples of whole blood by multiparametric flow cytometry (Becton Dickinson, Franklin Lakes, NJ, USA, FACSCanto II). The following fluorochrome-labeled mAbs against human Ags were obtained from Becton Dickinson: CD3 PE-Cy7, CD 16 APC-Cy7, CD158b1 FITC, CD20-PE, CD45-FITC, CD69-FITC and NKG2D-APC, Lineage-FITC, HLADR-APC-Cy7, CD11c-PECy5, CD45RA-PE-Cy5, CCR7-PE and CD80-PE. Fluorochromelabeled mAbs against CD19-PE, CD56-APC, CD25-PE, CD158 a,h-PE and NKp44-PE were obtained from Beckman Coulter (Fullerton, CA, USA). Fluorochrome-labeled mAbs against CD158e (KIR 3DL1)-PE, CD69-PE, T cells were defined as CD3 þ and CD56À cells. CD4T cells were defined as CD3 þ , CD4 þ and CD56À cells. CD8T cells were defined as CD3 þ , CD8 þ and CD56À cells. Naive T cells were defined as being CD45RA and CCR7 double positive. Memory T cells were defined as the sum of CD45RAÀ, CCR7 þ , CD45RA and CCR7 double negative and CD45RA þ and CCR7À cells. NKT cells were defined as double CD3 and CD56 þ cells. B lymphocytes were defined as CD19 and CD20 double-positive cells. DCs were defined as lineage (Lin)À HLA-DR þ cells. The DC1 subset (myeloid DC) was defined as LinÀ, HLA-DR þ and CD11c þ cells. DC2 subset (lymphoid DC) was defined as LinÀ, HLA-DR þ , CD11cÀ and BDCA4 þ cells. The DC1
) was defined as containing LinÀ, HLA-DR þ , CD11cÀ and BDCA4À cells.
KIR genotyping and KIR ligand (HLA-I typing)
Fifteen human KIR genes and two pseudogenes were analyzed by PCR with a KIR typing kit (Miltenyi Biotec). KIR A haplotype was defined by the absence of all 2DS1, 2DS2, 2DS3 and 3DS1, as well as the presence of 2DS4 as the sole KIR-activating receptor. KIR B haplotype was determined by the presence of any activating genes except 2DS4. KIR ligand HLA-C allotypes (C1 and C2) and HLA-B allotypes (Bw4) were determined using highresolution PCR-sequence-based typing.
Cytotoxicity assays
The natural cytotoxicity of NK cells was monitored in a conventional 2-h europium-TDA release assay (Perkin-Elmer Wallac, Turku, Finland) with an effector/target ratio of 3:1 as described previously.
14 K562 (erythroleukemia cell line) was used as a target cell. In brief, target cells were labeled with a fluorescence-enhancing ligand (BATDA). This hydrophobic ligand quickly penetrates the cell membrane. Within the cell, hydrolysis of ester bonds results in the ligand becoming hydrophilic and therefore unable to pass through the cell membrane. Cytolysis, however, results in the release of the ligand and reaction of the ligand with the europium to form a stable fluorescing chelate, which is evaluated fluorometrically (Infinite F200 reader TECAN Group Ltd, Männedorf, Switzerland). The number of NK cells was calculated by multiplying the lymphocyte counts with the percentage of CD3À CD56 þ NK cells.
The following formulae were used to calculate spontaneous and specific cytotoxicity:
% Specific release¼ (Experimental releaseÀspontaneous release)/ (Maximum releaseÀspontaneous release) Â 100. % Spontaneous release ¼ (Spontaneous releaseÀbackground)/ (Maximum releaseÀbackground) Â 100.
IL-15 and a-CpG-stimulated NK cells
Fresh PBMCs were stimulated overnight with 10 ng/mL IL-15 (CellGro/ CellGenix, Freiburg, Germany) or 10 mg/mL a-CpG (Enzo Life Sciences AG). Cultures were performed in complete culture medium (RPMI 1640 supplemented with 10% of heat-inactivated fetal bovine serum, 100 IU/ mL penicillin, 100 ng/mL streptomycin and 2 mM/L-glutamine) in a humidified atmosphere of 5% CO 2 and 95% air. Cytotoxicity was performed as described above.
Statistical analysis
Data were analyzed as of April 2011. Results are given in means ± s.e., unless otherwise indicated. Non-parametric Wilcoxon tests were used to compare immune reconstitution between types of donors (HP vs MUD). A chi square test was used to investigate whether distributions of categorical variables differ from one another. EFS was estimated from the time of HSCT by the Kaplan --Meier method. Relapse and toxic death were defined as events. EFS and type of donor (MUD vs HP), disease status at HSCT (1 a CR vs X2 a CR), and immune subset reconstitution (defined as high when the population was higher than the 50th percentile and low when the immune population was lower than the 50th percentile) were estimated using the univariate Kaplan --Meier method and compared using the logrank test, Po0.05 was considered significant.
RESULTS

T-cell and T-cell-subset reconstitution
We observed a rapid T-cell engraftment with a median of 530 ± 206/mL CD3 þ cells on day 30, 565 ± 167/mL on day 60 and 857±326/mL on day 90. The T-cell subset was inverted with a median of 167±64/mL CD4 þ cells vs 364±174/mL CD8 þ cells on day 30, 155 ± 47/mL vs 410 ± 119/mL on day 60 and 217 ± 72/mL vs 537 ± 192/mL on day 90. Furthermore, we analyzed naive T cells and memory T cells. We observed a delayed reconstitution of naive T cells, whereas the memory T cells reconstituted quickly, with a median of 164 ± 50/mL CD4 memory cells and 362 ± 135/mL CD8 memory cells on day 30. CD8 and CD8 memory T-cell recovery in the first month was faster in HP than in MUD HSCT (730 ± 208/mL vs 85 ± 37/mL, and 723 ± 274/mL vs 83 ± 29 cells/mL, respectively, Po0.05; Table 2 , Figures 1 and 2 ).
NKT-cell reconstitution NKT-cell recovery was delayed with a median of 2.76 ± 0.17, 3.9±0.3 and 5.2±1.1/mL on days þ 30, þ 60 and þ 90, respectively. No difference was found between MUD and HP HSCT (Table 2 and Figure 2 ). B-cell reconstitution Reconstitution of B lymphocytes was delayed, with a median of 32 ± 14, 120 ± 33 and 99 ± 47/mL on days þ 30, þ 60 and þ 90, respectively. No difference was found between MUD and HP HSCT (Table 2 and Figure 2 ).
DC reconstitution
After HSCT, we observed a gradual increase in the DC population over time, with median of 20.2 ± 4.4 cells/mL on day 30, 32.5 ± 9.8 cells/mL on day 60 and 33.7 ± 10.6 cells/mL on day 90. DC reconstitution was dominated by the DC1 À DC2 À lymphoid DC subset with a median of 8.9±2.5 cells/mL on day 30, 18.7±7.3 cells/mL on day 60 and 18.8 ± 9 cells/mL on day 90. DC1 À DC2 þ lymphoid DC subset reconstitution was slow, with a median of 5.6±1.5 cells/mL on day 30, 3.3±1.3 cells/mL on day 60 and 3.2±1.35 cells/mL on day 90. No difference in the lymphoid DC subset was found between MUD vs HP HSCT. Importantly, we observed a significant correlation between the number of lymphoid DC2 À cells on day þ 60 and patient survival ( Figure 3 ). This impact was due to a higher incidence of deaths caused by infections in low DC2
À patients vs high DC2 À (57% vs 0%, P ¼ 0.03), respectively.
The myeloid DC1 subset was faster in MUD compared with HP transplants (10.1 ± 3 vs 2.6 ± 1/mL in the first month, P ¼ 0.02). Maturation marker CD80 was expressed in 13% of DCs on day 30, decreasing to 5% on day 60 and 6% on day 90. CD80 expression in the DC1 À DC2 À subset was higher in HP in the first 2 months after HSCT than in MUD (26 ± 6.98 vs 5 ± 1.4/ml, P ¼ 0.04 and 28 ± 12 vs 2 ± 0.8/mL, respectively, P ¼ 0.05; Table 2 and Figure 1 ).
NK-cell and subset reconstitution NK-cell engraftment was rapid with normal values on day þ 30 (274±49/mL). The CD56 bright population decreased from a median of 76±26 cells/mL on day 30 to 27±2.6 cells/mL on day 60 and 30  60  90  30  60  90  30  60  90  30  60  90   T cell  530±206  565±167  857±326  870±453  477±242  983±588 226±13  621±238  652±232  0.07  NS  NS  CD4  167±64  155±47  217±72  141±76  102±52  305±134 138±99  179±69  198±43  NS  NS  NS  CD8 364 Among the inhibitory receptors (iKIRs), we found a slow acquisition of KIR receptors with a median of 5.1% of cells expressing KIR2DL1, a median of 13.7% cells expressing KIR2DL2 and a median of 1.6% cells expressing KIR3DL1 on day þ 30. The KIRs showed a delayed reconstitution with low expression level up to day þ 90 when compared with their donors, especially KIR2DL2, Po0.05 (Figure 4 ).
Activating receptor NKp44 showed a low expression with a median of 5.7% on day þ 60. NKp46 also showed a low expression with a median of 5.5% on day þ 90, Po0.05. An increased expression of activating receptor NKp30 was observed on day þ 60 (42%) and a decreased expression on day þ 90 (10.5%). NKG2D was highly expressed early on after HSCT. When we compared activating and lectin-like receptor expression in recipients vs donors, we observed lower levels of NKp46 and NKp44 (4.3% and 5.2% on day 30, 2.5% and 5.7% on day 60, and 5.5% and 2.8% on day 90 vs 15% in donors, respectively, Po0.05) and higher levels of NKp30 on day þ 60 (42.7% vs 15.6% in donors, Po0.05; Figure 4) .
A decreased expression of activation markers was observed on day þ 60 on CD69 and CD25 (5.6% and 1.8%, compared with 19.3% and 4.5% in donors, Po0.05, respectively). A decreased expression of TLR9 was observed on day þ 60 (13% compared with 42% in donors) and an increased expression of TLR4 was observed on day þ 90 (59% compared with 10% in donors, Po0.05, Figure 4 ).
NK-cell cytotoxicity
After HSCT, we observed low NK-cell cytotoxicity with a median of 16% on day 30, 18% on day 60 and 22% on day 90 with an effector:target ratio of 3:1, Po0.05. Overnight TLR9 ligand (a-CpG) or IL-15 stimulation, however, increased significantly the in vitro NK-cell cytotoxicity, over the reference donor values, Po0.05 (Figure 4 ). any difference in EFS (Table 3) Results showed CD3 lineagespecific full donor chimerism on day 30, 80 ± 10% on day 60 and 88 ± 9% on day 90. Primary engraftment failure was observed in two patients (both from the HP group). In these patients, CD3 lineage-specific chimerism was fully recipient. They all are alive with autologous cell recovery and in CR at last follow-up. Secondary graft failure was observed in two patients (both from the HP group). One of these patients died due to pulmonary hemorrhage with a second transplantation, and the other is alive with autologous recovery and in CR. Seven patients (23%) had grade I --II acute GvHD (3 in the HP group and 4 in MUD), which resolved with topical steroid treatment. Four patients (17%) developed severe acute GVHD, three patients grade III (2 in HP and 1 in the MUD group) and one patient grade IV in the MUD group. Residual T-lymphocyte cells in the graft were below 50 Â 10 3 /kg in all cases (Supplementary Table 4) ; chronic GVHD was observed in two cases (both in the HP group, one limited and one extensive; this patient had developed stage III acute GVHD, previously). Non-relapse mortality occurred in 7/30 (23%); 3/15 (20%) in HP and 4/15 (26%) in MUD HSCT. To date five patients have died because of infections: disseminated aspergillosis (n ¼ 1), disseminated varicella zoster (n ¼ 1), rubella (n ¼ 1) and CMV pneumonia (n ¼ 2). Two further patients died of pulmonary hemorrhage. Eight patients (26%) relapsed (five from the HP group and three from the MUD group). All died, except one from the MUD group, who received a second MUD transplant and is alive in CR. Currently, 15/30 (50%) patients are alive and in CR, resulting in a Kaplan --Meier EFS of 50% (46% for HP and 53% for MUD HSCT), with a median follow-up of 548 days (range 51 --1274). EFS for patients in first CR was 73 ± 1% (71 ± 17% in HP and 75 ± 15% in MUD HSCT). EFS for patients in second or subsequent remission was 26 ± 11% (25 ± 15% in HP and 28 ± 16% in MUD HSCT, Table 1 and Figure 5 ).
NK-cell alloreactivity
DISCUSSION
In this study, we analyzed in detail the early immune reconstitution and clinical outcome of children receiving CD3/CD19-depleted grafts with fludarabine-based RIC without serotherapy. CD3/CD19 depletion was chosen instead of CD34 þ selection as non-pharmacological GVHD prophylaxis, to facilitate engraftment and to augment the GVL effect by retaining large numbers of NK cells and myeloid cells in the graft. In addition, we used pharmacological GvHD prophylaxis because of high amounts of residual T cells in the graft (77 ± 25 Â 10 3 /kg). Indeed, we observed a very fast recovery of NK cells and T cells. Fast NK-cell recovery was observed in the HP setting by Pfeiffer et al. 8 in CD3/CD19-depleted HSCT in children. Fast T-cell recovery, dominated by CD8 memory T-cell subsets, constitutes a novel observation in our study. We attributed the fast NK and T recovery to the conditioning without serotherapy. Campath and antithymocyte globulin, in particular, have been associated with high risk of infection and relapse because of their long half-life. 15 However, it is remarkable that within the first 90 days there is not much expansion of CD3 þ and CD4 þ memory T cells, with the notably high values on day þ30.
Our data showed an acceptable rate of engraftment failure in HP HSCT, 4/15 (27%), although lower than that from other groups using OKT-3. 8 The rates of engraftment failure from adult patients using similar conditioning regimens with antithymocyte globulin are similar, 22%. 16 Remarkably, autologous recovery without evidence of disease was observed in three of four patients. Autologous CD8 þ T-cell and NK-cell expansion from residual host cells might have developed a host vs leukemia effect. 17 --22 Different strategies, such as co-transplantation of ex-vivo expanded mesenchymal stromal cells and reconditioning regimen with TLI and serotherapy, have improved engraftment in HP setting. 23, 24 CD8 memory cells dominated T-cell recovery in our patients. Naive T-cell recovery is negligible in this short timeframe (o5 cells/mL), even in our pediatric population with a functioning thymus and with low GvHD incidence. The rapid recovery of memory CD8 þ cells may explain the low incidence of infection in our population. However, the low numbers of naive T cells may explain the high incidence of early relapse in patients 4CR1.
Although NK-cell alloreactivity has been proposed as the major immune effector cell in the HP setting, T-cell-mediated GVL effect is also important. However, the mere presence of T cells in the graft is not sufficient to mediate GVL reactivity. 25 An effective GVL effect also requires that DCs present the Ags expressed by leukemia cells. 26 Early after HSCT, direct presentation of Ags by residual host DCs derived from malignant cells may provide a sufficient source of Ags to drive effective GVL. 27 In our study, normal counts of peripheral DCs were found on day þ 60, dominated by lymphoid DC2 subtypes. Importantly, we observed a significant correlation between the number of lymphoid DC2 À cells on day þ 60 and patient survival (Figure 3) . Although it did not have an impact on relapse, patients whose lymphoid DC2 À cells on day þ 60 were lower than the median had a poorer OS, which was due to the higher incidence of deaths caused by infections (Supplementary Table 5 ). This clinical observation is in agreement with the findings in adult patients after RIC from HLAidentical siblings. 12 We observed that myeloid DCs were higher in MUD than in HP transplants. However, upregulation of the CD80 marker was higher in HP settings than in MUD. Previous studies have shown that a high donor DC content in the graft may increase leukemia relapse because of the suppressive effects on NK cells through IL-6 and IL1-10, but fast DC recovery in the recipients may increase survival by reducing infections. 28 Unfortunately, in our RIC setting, we did not determine the chimerism status among DCs because of the small amount of cells available. Nevertheless, post HSCT infusion of non-alloreactive T cells and DCs could be a strategy to minimize infection post HSCT.
Beyond the adaptive immune response, the innate NK-cell response has an important role in HP HSCT. 29 A lack of inhibition by inhibitory receptors and a positive trigger by activating signals determine NK alloreactivity. 30 We have studied in depth the NKcell subset and receptor recovery. We observed a low expression of iKIR. This is consistent with the results of Federmann et al. 31 in adult patients receiving RIC and CD3/CD19-depleted grafts. As iKIRs are necessary for NK cytotoxicity in missing-self recognition on leukemia cells, faster receptor reconstitution might be an advantage to establish GVL. In this regard, decreased NK-cell cytotoxicity was observed in our patients in part due to slow iKIR acquisition. We also observed low NKp46 and NKp44 expression during the first 100 days after HSCT. This low level of NKp46 and NKp44 is consistent with an immature CD56 bright NK phenotype. In a recent publication in HLA-matched MUD HSCT, NKp46 bright positive cells were found to be important to preserve NK cytotoxicity. 30 We found that NKp30 and NKG2D expression were less affected after HSCT; unfortunately, we did not study their ligands in leukemia blasts to assess their clinical importance. Overall we observed weak cytotoxicity against the HLA class Inegative K562 cell line early after HSCT. This early period seems to be crucial for leukemia progression, as all the relapses in our patients occurred between the third and sixth months after HP transplants. These data are in agreement with the results published from HP HSCT in AML patients. 32 Notably, overnight IL-15 or a-CpG stimulation can dramatically increase NK cytotoxicity ( Figure 4 ) without modifying NK-cell numbers and phenotype (data not shown). These results highlight the ability of TLR ligands and IL-15 to directly activate the NK-cell response. In this regard, recent studies suggested that TLR ligands might improve the efficacy of immunotherapy for chronic lymphocytic leukemia and non-Hodgkin lymphoma by enhancing NK cells and T cells, and by modifying the angiogenesis at the tumor microenvironment. 33, 34 Furthermore, a-CpG signaling has been proposed to function as an immune antitumor stimulus by NK/CD4 DC crosstalk activation. 35 As a result of the small sample size, NK cells vs leukemia effect according to any alloreactivity model, as 'KIR ligand-ligand mismatch model', 'KIR receptor-ligand mismatch model', 'KIR B haplotype' or 'maternal donor effect' was not able to influence the outcome. 29, 36, 37 However, it should be emphasized how relapse events were null in KIR ligand --ligand mismatch patient --donor pairs.
In our study, the only advanced stage disease was associated with decreased EFS. In our opinion, if HSCT is indicated, the absence of a matched donor should not be a limitation. HSCT performed with HLA-haploidentical donors is feasible and results are encouraging, 38 especially if the leukemia is in first CR. However, new strategies should be developed for second or subsequent CR. Our study provides useful clinical and biological data that are important for future HSCT strategies in childhood acute leukemia.
